Akoya Biosciences, Inc., a life sciences technology company, provides spatial biology solutions focused on transforming discovery and clinical research in North America, the Asia Pacific, Europe, the Middle East, and Africa. The company offers PhenoCycler instrument, a compact bench-top fluidics system that integrates with a companion microscope to automate image acquisition; and PhenoImager platform that enables researchers to visualize, analyze, quantify, and phenotype cells in situ, in fresh frozen or FFPE tissue sections, and tissue microarrays utilizing an automated and high-throughput workflow. It also provides PhenoCycler and PhenoImager reagents; and biopharma services. In addition, the company offers Proxima, a cloud-based platform to store, analyze, and share spatial data; inForm Tissue, an automated image analysis software package for accurately visualizing and quantifying biomarkers in tissue sections; Phenoptr, which provides functions that consolidate and analyze output tables created by inForm software; and phenoptrReports, a software that generates shareable reports and visualizations based on the phenoptr output in an intuitive front-end GUI. The company was incorporated in 2015 and is headquartered in Marlborough, Massachusetts.

Akoya Biosciences, Inc.

As The Spatial Biology Company®, Akoya Biosciences’ mission is to bring context to the world of biology and human health through the power of spatial phenotyping. The company offers comprehensive single-cell imaging solutions that allow researchers to phenotype cells with spatial context and visualize how they organize and interact to influence disease progression and response to therapy. 

Akoya offers a full continuum of spatial phenotyping solutions to serve the diverse needs of researchers across discovery, translational and clinical research: PhenoCode™ Panels, PhenoCycler®, PhenoImager® Fusion, and PhenoImager HT Instruments.

View our open job descriptions: www.akoyabio.com/careers

Follow us on Twitter: www.twitter.com/AkoyaBio   

Subscribe to our YouTube channel: www.youtube.com/c/AkoyaBiosciences 

Innovatus Capital Partners

Telegraph Hill Partners

Piper Jaffray Merchant Banking

Thomas Schnettler

We are excited to welcome Crown Bioscience as an Akoya-qualified service provider! Headquartered in San Diego, CA, Crown Bioscience aims to support drug discovery through translational research across oncology and immuno-oncology.

By joining our Contract Research Organization Network, Crown Bioscience will utilize Akoya's Phenomager HT platform to offer advanced multispectral imaging technology, easily integrated into high-throughput workflows to accommodate projects regardless of scale.

Explore Crown Bioscience's digital pathology technologies: https://bit.ly/3T0ALxY

#oncology #immunooncology #drugdiscovery #phenoimager #crownbioscience

This groundbreaking study, published in Nature using our PhenoImager HT platform, offers a fresh perspective on the pathology and heterogeneity of rheumatoid arthritis. The findings hold promise for developing innovative targeted treatments for patients with this condition. 

🙌 Kudos to the authors for their valuable contribution to understanding this debilitating, autoimmune disease without a cure!

#FridayRead #PhenoImager #AkoyaInAction #SpatialBiology #RheumatoidArthritis

Join us at the Cancer Neuroscience Symposium at the MD Anderson Cancer Center in Houston, Texas!

The Akoya team will be there today and tomorrow and will be happy to discuss how our spatial biology solutions are making a difference in neuroscience and cancer research. 

Not attending? Explore our solutions on our website: https://bit.ly/47GvLFB

#SpatialBiology #Neuroscience #MDAnderson #CancerResearch #Immunology

Dr. Tom Lund and his team at the Integrated Pathology Unit (IPU) in London have consistently used our instruments, with the PhenoImager HT serving as a central resource in their laboratory.

The IPU, a collaborative effort between The Institute of Cancer Research and the Royal Marsden Hospital, is crucial in bridging clinical, translational, and basic research. Dr. Lund attributes the IPU's flexibility to their tissue-agnostic Akoya technology, which requires minimal tissue-specific optimization, allowing seamless adaptation to diverse research requirements.

We are thankful for Dr. Lund's ongoing support of our technology. We are excited to witness his lab's advancements in further understanding and treating cancer through multiplex immunofluorescence.

#spatialbiology #digitalpathology #multiplex #phenoimager SelectScience®

📢 Tomorrow is part 1 of a 2-part webinar series on fusing single-cell genomics and spatial proteomics with MaxFuse!

Hear Garry Nolan, Ph.D., discuss MaxFuse, a new AI algorithm that provides reliable, fast, and cost-effective integration of spatial proteomic data with single-cell transcriptomic and epigenomic datasets. 

This webinar will be offered at two different times on Feb 28th; attendees can join at 3 AM PT/6 AM ET/12 PM CET or 9 AM PT/12 PM ET/6 PM CET. 

Hope to see you there!

#spatialbiology #spatialproteomics #maxfuse #singlecell #genomics Genetic Engineering & Biotechnology News 

	Dec '19	Dec '20	Dec '21	Dec '22	Dec '23
net income	-14.75M -	-16.71M 13.25%	-42.94M 157.00%	-70.64M 64.53%	-63.32M 10.36%
depreciation and amortization	3.06M -	3.81M 24.88%	4.79M 25.61%	7.15M 49.19%	8.89M 24.35%
deferred income tax	156K -	7K 95.51%	-155K 2,314.29%	35K 122.58%	-51K 245.71%
stock based compensation	153K -	477K 211.76%	4.04M 746.75%	7.43M 83.96%	10.44M 40.47%
change in working capital	-1.38M -	2.39M 273.86%	-4.56M 290.52%	2.16M 147.45%	-12.06M 657.21%
accounts receivables	-3.37M -	6.70M 298.55%	-2.97M 144.41%	-285K 90.42%	-7.26M 2,449.12%
inventory	-4.01M -	-684K 82.93%	-4.63M 576.61%	-5.37M 16.12%	-6.33M 17.83%
accounts payables	-49K -	-3.04M 6,114.29%	4.36M 243.22%	1.19M 72.64%	1.15M 3.77%
other working capital	6.05M -	-574K 109.48%	-1.32M 129.97%	6.63M 602.27%	391K 94.10%
other non cash items	-1.01M -	3.17M 413.24%	2.75M 13.19%	367K 86.66%	5.21M 1,318.53%
net cash provided by operating activities	-13.78M -	-6.84M 50.33%	-36.07M 427.08%	-53.50M 48.32%	-50.90M 4.85%
investments in property plant and equipment	-2.87M -	-3.29M 14.85%	-5.09M 54.60%	-7.36M 44.48%	-3.65M 50.37%
acquisitions net		145K -		55K -
purchases of investments	-10M -	-145K 98.55%		-40.77M -
sales maturities of investments		10.17M -		34M -	7M 79.41%
other investing activites	-23K -	-145K 530.43%
net cash used for investing activites	-12.89M -	6.73M 152.19%	-5.09M 175.71%	-14.08M 176.38%	3.35M 123.77%
debt repayment	-25.04M -	-25.19M 0.60%	-322K 98.72%	-621K 92.86%	-10.54M 1,597.42%
common stock issued	24.83M -	122K 99.51%	138.55M 113,468.03%	447K 99.68%	48.31M 10,708.28%
common stock repurchased			1.44M -
dividends paid			-1.44M -
other financing activites	28.77M -	30.55M 6.19%	-1.20M 103.91%	28.90M 2,516.39%	19.07M 34.01%
net cash used provided by financing activities	28.56M -	5.49M 80.79%	137.03M 2,397.90%	28.73M 79.04%	56.84M 97.88%
effect of forex changes on cash					-396K -
net change in cash	1.89M -	5.37M 183.73%	95.87M 1,685.01%	-38.85M 140.52%	8.90M 122.90%
cash at beginning of period	10.24M -	12.14M 18.48%	17.51M 44.25%	113.38M 547.60%	74.23M 34.53%
cash at end of period	12.14M -	17.51M 44.25%	113.38M 547.60%	74.53M 34.26%	83.13M 11.53%
operating cash flow	-13.78M -	-6.84M 50.33%	-36.07M 427.08%	-53.50M 48.32%	-50.90M 4.85%
capital expenditure	-2.87M -	-3.29M 14.85%	-5.09M 54.60%	-7.36M 44.48%	-3.65M 50.37%
free cash flow	-16.64M -	-10.14M 39.09%	-41.16M 306.02%	-60.86M 47.85%	-54.55M 10.36%

COM:AKOYABIO

Akoya Biosciences, Inc.

Last Close

2.12

22/11 21:00

Market Cap

102.72M

Beta: -

Volume Today

81.11K

Avg: -

Preview